Matching adults with chronic pain to effective treatments
Matching Adults to Treatments for Chronic Pain (MATCH) Study
This study is trying to find out which treatment works best for people with chronic pain by matching them to options like therapy or usual care based on their individual needs.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 330 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Washington Academic / other |
| Locations | 3 sites (Seattle, Washington and 2 other locations) |
| Trial ID | NCT05699252 on ClinicalTrials.gov |
What this trial studies
This study aims to identify which patients with chronic pain benefit most from different treatment approaches, including Cognitive Behavioral Therapy (CBT), Hypnotic Cognitive Therapy (HYP-CT), and Mindfulness-Based Cognitive Therapy (MBCT). Participants will be randomized to one of these treatments or usual care, and their pain intensity will be measured before and after treatment. The study will focus on five predictive markers assessed prior to treatment to determine their influence on treatment outcomes. The goal is to enhance personalized treatment strategies for chronic pain management.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who experience chronic pain with an average intensity of 3 or higher on a 0-10 scale.
Not a fit: Patients who are currently participating in another clinical trial for chronic pain may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more effective, personalized treatment options for individuals suffering from chronic pain.
How similar studies have performed: Previous studies have shown promise in using complementary and integrative health interventions for chronic pain, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * ≥ 18 years old. * Having chronic pain, operationalized as average pain intensity in the last week rated as ≥ 3 on a 0-10 Numerical Rating Scale (NRS) and having pain on most days for 3 months or more. * Able to read, speak, and understand English. * Willingness to be randomized to condition and use videoconferencing with audio and video enabled. * Access to a private place with adequate internet reception to support participation in videoconferencing treatment sessions. * Not currently participating in another clinical trial or interventional study for chronic pain and willing to refrain from participation in any other clinical trial or interventional study for chronic pain during active participation in this study. * Willing, able, and committed to participate in an in-person EEG assessment. * Able to use a smart phone, tablet, or computer independently to access email and webpages or have someone available in their home who can help them with initial session set-up and then leave for the treatment sessions. Exclusion Criteria: The exclusion criteria for Veteran participants will be assessed via self-report and verified by VA medical records chart review. Eligibility for non-Veteran participants will be assessed by self-report (no medical records chart review). An individual who meets any of the following criteria at the time of screening will be excluded from participation in this study and will not be enrolled: * Active suicidal ideation/intent indicating significant risk. * Unstable medical or psychiatric condition (e.g., mania, psychotic symptoms) that would interfere with study participation. * Behavioral issues noted in the record or observed during the screening process that would interfere with appropriate or safe videoconferencing treatment session participation or study procedures. * Alcohol abuse (operationalized as scoring 15 or more if male or 13 or more if female on the Alcohol Use Disorders Identification Test), or any illicit drugs, all of which may impact EEG measures. * Severe cognitive impairment defined as two or more errors on the Six-Item Screener. * Having an EEG confounder (e.g., congenital or acquired skull defects, missing sections or holes in the skull, or plates, screws, or other implants within the skull or brain) that would interfere with reliable EEG data collection. * Active cancer treatment or primary pain is due to cancer.
Where this trial is running
Seattle, Washington and 2 other locations
- University of Washington, Ninth and Jefferson Building — Seattle, Washington, United States (Recruiting)
- VA Puget Sound Health Care System, Seattle Division — Seattle, Washington, United States (Recruiting)
- VA Puget Sound Health Care System, American Lake — Tacoma, Washington, United States (Recruiting)
Study contacts
- Principal investigator: Mark P Jensen, Ph.D. — University of Washington
- Study coordinator: Sydney Drever, B.A.
- Email: drevers@uw.edu
- Phone: 206-744-4811
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.